Liepins Edgars

News and Events

Working Groups

Short-Term Scientific Missions

Management Committee

Members

COST Action CA15203 (2016-2021): MitoEAGLE
Evolution-Age-Gender-Lifestyle-Environment: mitochondrial fitness mapping

Liepins Edgars

MitoPedia topics: EAGLE

COST: Member COST WG1: WG1 COST WG2: WG2

COST Mentor: Mentor

MC Member - Management Committee MitoEAGLE

Name	Liepinsh Edgars, Dr.
Institution	Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, LV
Address	Aizkraukles Street 21, LV-1006
City	Riga
State/Province
Country	Latvia
Email	[email protected]
Weblink
O2k-Network Lab	LV Riga Liepins E

Labels:

Publications

	Published	Reference
Liepinsh 2024 Br J Pharmacol	2024	Liepinsh E, Zvejniece L, Clemensson L, Ozola M, Vavers E, Cirule H, Korzh S, Skuja S, Groma V, Briviba M, Grinberga S, Liu W, Olszewski P, Gentreau M, Fredriksson R, Dambrova M, Schiöth HB (2024) Hydroxymethylglutaryl-CoA reductase activity is essential for mitochondrial β-oxidation of fatty acids to prevent lethal accumulation of long-chain acylcarnitines in the mouse liver. Br J Pharmacol [Epub ahead of print]. https://doi.org/10.1111/bph.16363
Cardoso 2024 MitoFit FAO	2024	Cardoso LHD, Cecatto C, Ozola M, Korzh S, Zvejniece L, Gukalova B, Doerrier C, Dambrova M, Makrecka-Kuka M, Gnaiger E, Liepinsh E (2024) Fatty acid β-oxidation in brain mitochondria: Insights from high-resolution respirometry in mouse, rat and Drosophila brain, ischemia and aging models. MitoFit Preprints 2023.10. https://doi.org/10.26124/mitofit:2023-0010.v2
Zvejniece 2023 Biomed Pharmacother	2023	Zvejniece L, Svalbe B, Vavers E, Ozola M, Grinberga S, Gukalova B, Sevostjanovs E, Liepinsh E, Dambrova M (2023) Decreased long-chain acylcarnitine content increases mitochondrial coupling efficiency and prevents ischemia-induced brain damage in rats.
Dambrova 2022 MitoFit	2022	Dambrova M, Cecatto C, Vilskersts R, Liepinsh E (2022) Mitochondrial metabolites acylcarnitines: therapeutic potential and drug targets. https://doi.org/10.26124/mitofit:2022-0020 2022-11-25 published in Bioenerg Commun 2022.15.
Dambrova 2022 BEC	2022	Dambrova M, Cecatto C, Vilskersts R, Liepinsh E (2022) Mitochondrial metabolites acylcarnitines: therapeutic potential and drug targets. Bioenerg Commun 2022.15. https://doi.org/10.26124/bec:2022-0015
Dambrova 2022 Pharmacol Rev	2022	Dambrova M, Makrecka-Kuka M, Kuka J, Vilskersts R, Nordberg D, Attwood MM, Smesny S, Sen ZD, Guo AC, Oler E, Tian S, Zheng J, Wishart DS, Liepinsh E, Schioth HB. (2022) Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials. https://doi.org/10.1124/pharmrev.121.000408
Liepinsh 2021 Free Radic Biol Med	2021	Liepinsh E, Kuka J, Vilks K, Svalbe B, Stelfa G, Vilskersts R, Sevostjanovs E, Goldins NR, Groma V, Grinberga S, Plaas M, Makrecka-Kuka M, Dambrova M (2021) Low cardiac content of long-chain acylcarnitines in TMLHE knockout mice prevents ischaemia-reperfusion-induced mitochondrial and cardiac damage. Free Radic Biol Med 177:370-80.
BEC 2020.1 doi10.26124bec2020-0001.v1	2020	Gnaiger E et al ― MitoEAGLE Task Group (2020) Mitochondrial physiology. Bioenerg Commun 2020.1. https://doi.org/10.26124/bec:2020-0001.v1
Makrecka-Kuka 2020 Cardiovasc Drugs Ther	2020	Makrecka-Kuka Marina, Korzh Stanislava, Videja Melita, Vilks Karlis, Cirule Helena, Kuka Janis, Dambrova Maija, Liepinsh Edgars (2020) Empagliflozin protects cardiac mitochondrial fatty acid metabolism in a mouse model of diet-induced lipid overload. Cardiovasc Drugs Ther 34:791-97.
Liepinsh 2020 Physiol Rep	2020	Liepinsh E, Makarova E, Plakane L, Konrade I, Liepins K, Videja M, Sevostjanovs E, Grinberga S, Makrecka-Kuka M, Dambrova M (2020) Low-intensity exercise stimulates bioenergetics and increases fat oxidation in mitochondria of blood mononuclear cells from sedentary adults. Physiol Rep 8:e14489.
Makrecka-Kuka 2019 Acta Physiol (Oxf)	2019	Makrecka-Kuka M, Liepinsh E, Murray AJ, Lemieux H, Dambrova M, Tepp K, Puurand M, Käämbre T, Han WH, de Goede P, O'Brien KA, Turan B, Tuncay E, Olgar Y, Rolo AP, Palmeira CM, Boardman NT, Wüst RCI, Larsen TS (2019) Altered mitochondrial metabolism in the insulin-resistant heart. Acta Physiol (Oxf) 228:e13430.
Makrecka-Kuka 2017 Toxicol Lett	2017	Makrecka-Kuka M, Volska K, Antone U, Vilskersts R, Grinberga S, Bandere D, Liepinsh E, Dambrova M (2017) Trimethylamine N-oxide impairs pyruvate and fatty acid oxidation in cardiac mitochondria. Toxicol Lett 267:32-8.
Makrecka-Kuka 2017 Sci Rep	2017	Makrecka-Kuka M, Sevostjanovs E, Vilks K, Volska K, Antone U, Kuka J, Makarova E, Pugovics O, Dambrova M, Liepinsh E (2017) Plasma acylcarnitine concentrations reflect the acylcarnitine profile in cardiac tissues. Sci Rep 7:17528.
Liepinsh 2016 Biochem J	2016	Liepinsh E, Makrecka-Kuka M, Volska K, Kuka J, Makarova E, Antone U, Sevostjanovs E, Vilskersts R, Strods A, Tars K, Dambrova M (2016) Long-chain acylcarnitines determine ischaemia/reperfusion-induced damage in heart mitochondria. Biochem J 473:1191-202.

Abstracts

	Published	Reference
Cecatto 2023 BPS2023 San Diego	2023	Cecatto C, Schmitt Sabine, Cardoso L, Videja M, Dambrova M, Makrecka-Kuka M, Liepinsh E, Gnaiger E (2023) Contribution of fatty acid oxidation to respiratory control in brain mitochondria. 67th Annual Meeting of the Biophysical Society.
Dambrova 2022 Abstract Bioblast	2022	8.2. «10+5» Dambrova Maija, Vilskersts R, Liepinsh E(2022) Mitochondrial metabolites acylcarnitines: therapeutic potential and drug targets. Bioblast 2022: BEC Inaugural Conference. In: https://doi.org/10.26124/bec:2022-0001 »MitoFit Preprint«
Wuest 2019 MiPschool Coimbra	2019	Altered mitochondrial metabolism in the diabetic heart.
Lemieux 2019b MiP2019	2019	Altered mitochondrial metabolism in the diabetic heart.
Liepins 2018 MiP2018	2018	Mitochondrial and extramitochondrial effects of long-chain acylcarnitines.
Makrecka-Kuka 2018 MiP2018	2018	Fatty acid oxidation in brain: from aging to ischemia and sepsis.
Dambrova 2018 MiP2018	2018	L-Carnitine: from discovery to cardiometabolic risk markers.
Kuka 2018 MiP2018	2018	The discovery of methyl-GBB - acylcarnitine lowering as an effective strategy to treat cardiometabolic diseases.
Makarova 2018 MiP2018	2018	Plasma concentrations of fatty acids and acylcarnitines as biomarkers for diagnosis of insulin resistance in adipose and muscle tissues.
Volska 2018 MiP2018	2018	The mechanisms of long-chain acylcarnitine accumulation during ischemia.
Makrecka-Kuka 2018 MiPschool Tromso E1	2018	Cardiac fatty acid oxidation: from in vitro to in vivo.
Makrecka-Kuka 2017 Abstract MITOEAGLE Barcelona	2017	Fatty acid oxidation evaluation in mitochondria.
Makrecka-Kuka 2017 MiP2017	2017	Heart, brain and kidneys: who will survive? Tissue-specific changes in mitochondrial function in the experimental model of endotoxemia.
Makrecka-Kuka 2016 Abstract MitoFit Science Camp 2016	2016	Long-chain acylCoAs vs acylcarnitines in mitochondrial bioenergetics: from in vitro to in vivo.
Makrecka 2013 Abstract MiP2013	2013	Makrecka-Kuka M, Volska K, Kuka J, Liepins E, Dambrova M (2013) The accumulation of long chain acyl-carnitines is a major cause of mitochondrial damage during ischemia. Mitochondr Physiol Network 18.08.

MitoEAGLE Feedback

We are mostly interested in two WG: (1) Since we are working mostly with heart and muscles, we are interested in WG 2 - MitoEAGLE data repository in muscle and other tissues. (2) WG 1 - Standard operating procedures and user requirement document: Protocols, terminology, documentation. Since we have an expertise in fatty acid metabolism, we are specially interested in experimental protocols for the evaluation of mitochondrial capacities regarding fatty acid metabolism. Of course our parts of the WG are also in our interest. - Marina Makrecka-Kuka, Edgars Liepins (2016).

Participated at